Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Cash from Investing Activities (2016 - 2022)

Spero Therapeutics' Cash from Investing Activities history spans 6 years, with the latest figure at -$129000.0 for Q3 2022.

  • For Q3 2022, Cash from Investing Activities fell 100.76% year-over-year to -$129000.0; the TTM value through Jun 2023 reached -$129000.0, down 100.47%, while the annual FY2022 figure was $33.8 million, 340.65% up from the prior year.
  • Cash from Investing Activities reached -$129000.0 in Q3 2022 per SPRO's latest filing, down from $50.0 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $50.0 million in Q2 2022 to a low of -$72.6 million in Q3 2018.
  • Average Cash from Investing Activities over 5 years is -$88263.2, with a median of $3.9 million recorded in 2020.
  • Peak YoY movement for Cash from Investing Activities: skyrocketed 396.9% in 2019, then plummeted 869.5% in 2020.
  • A 5-year view of Cash from Investing Activities shows it stood at $7.3 million in 2018, then tumbled by 156.25% to -$4.1 million in 2019, then tumbled by 869.5% to -$39.7 million in 2020, then soared by 41.43% to -$23.3 million in 2021, then soared by 99.45% to -$129000.0 in 2022.
  • Per Business Quant, the three most recent readings for SPRO's Cash from Investing Activities are -$129000.0 (Q3 2022), $50.0 million (Q2 2022), and -$16.1 million (Q1 2022).